No Mortality Signal With Stellarex Low-Dose Paclitaxel DCB: ILLUMENATE Pivotal 4-Year Outcomes.

Sean Patrick LydenPeter L FariesKhusrow A K NiaziRavish SacharAsh JainMarianne BrodmannMartin WernerAmi SoodPrakash Krishnan

Published in: Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists (2022)

Stellarex DCB was associated with significantly higher patency compared with PTA through 3 years with no mortality difference detected through 4 years. The data from the ILLUMENATE Pivotal RCT support the long-term safety and efficacy of the low-dose Stellarex DCB.

Keyphrases

low dose
cardiovascular events
high dose
risk factors
big data
cardiovascular disease
coronary artery disease
type diabetes
adipose tissue
artificial intelligence